Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021

Mutations Associated with SARS-CoV-2 Variants of Concern, Benin, Early 2021

Anna-Lena Sander1, Anges Yadouleton1, Edmilson F. de Oliveira Filho, Carine Tchibozo, Gildas Hounkanrin, Yvette Badou, Praise Adewumi, Keke K. René, Dossou Ange, Salifou Sourakatou, Eclou Sedjro, Melchior A. J. Aïssi, Hinson Fidelia, Mamoudou Harouna Djingarey, Michael Nagel, Wendy Karen Jo, Andres Moreira-Soto, Christian Drosten, Olfert Landt, Victor Max Corman, Benjamin Hounkpatin, and Jan Felix DrexlerComments to Author 
Author affiliations: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany (A.-L. Sander, E.F. de Oliveira Filho, W.K. Jo, A. Moreira-Soto, C. Drosten, V.M. Corman, J.F. Drexler); Ecole Normale Supérieure de Natitingou, Natitingou, Benin (A. Yadouleton); Université Nationale des Sciences, Technologies, Ingénierie et Mathématiques (UNSTIM), Cotonou, Benin (A. Yadouleton); Laboratoire des Fièvres Hémorragiques Virales du Benin, Cotonou (A. Yadouleton, C. Tchibozo, G. Hounkanrin, Y. Badou, P. Adewumi); Ministry of Health, Cotonou (K.K. René, D. Ange, S. Sourakatou, B. Hounkpatin); Conseil National de Lutte contre le VIH-Sida, la Tuberculose, le Paludisme, les IST et les Epidémies, Cotonou (E. Sedjro, M.A. Joël Aïssi, H. Fidelia); World Health Organization Regional Office for Africa, Health Emergencies Programme, Brazzaville, Democratic Republic of the Congo (M.H. Djingarey); Deutsche Gesellschaft für Internationale Zusammenarbeit, Bonn, Germany (M. Nagel); German Centre for Infection Research (DZIF), associated partner Charité-Universitätsmedizin Berlin, Berlin (C. Drosten, V.M. Corman, J.F. Drexler); TIB Molbiol Syntheselabor GmbH, Berlin (O. Landt)

Main Article

Table 2

Hallmark mutations and PRNT50 results of Benin-derived severe acute respiratory syndrome coronavirus 2 lineages, Benin, 2021

Sample no. 251307 314235 251455 312541
Q52R, Del HV69/70, Del Y144, E484K, D614G, Q677H, F888L
Del HV69/70, Del Y144, F490S, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
L18F, L452R, N501Y, A653V, H655Y, D796Y, G1219V
Ins R214TDR, Q414K, D614G, T716I
Patient-derived samples
Mean titer (95% CI) 23 (–12.4 to 58.4) 35.5 (–12 to 83) 65.6 (–46.6 to 177.7) 148.9 (–86.59 to 384.3)
No. (%) neutralized 3/6 (50) 5/6 (83.3) 4/6 (66.7) 6/6 (100)
Titer difference†
52.2 (1.5-fold)
Vaccinee-derived samples
Mean titer (95% CI) 180.5 (102.8–258.1) 156.2 (33.6–278.7) 293.7 (57.1–530.2) 698.3 (446.8–949.9)
No. (%) neutralized 7/7 (100) 7/7 (100) 7/7 (100) 7/7 (100)
Titer difference† 136.7 161 23.5 –381.1‡

*PRNT50, 50% plaque reduction neutralization test. †Compared to variant B.1.153. ‡Lower titers against the early isolate compared with this Benin-derived isolate.

Main Article

1These first authors contributed equally to this article.

Page created: August 09, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.